# Bendamustine and Melphalan in Myeloma

> **NCT03187223** · PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 120 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Melphalan
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT03187223
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-20
- **Primary completion:** 2020-03-12
- **Final completion:** 2020-05-28
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03187223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03187223, "Bendamustine and Melphalan in Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03187223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*